Alluvi, previously BI 4744, offers a significant advance in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates remarkable results in research studies, arguably outperforming existing https://bookmarks-hit.com/story876587/alluvi-a-detailed-examination-into-the-drug-s-prospects